|Videos|December 2, 2022
Advent of Bispecific Antibodies for Relapsed/Refractory Follicular Lymphoma
Author(s)Matthew J. Matasar, MD, Laurie Sehn, MD
Expert perspectives on the advent of bispecific antibody therapy in relapsed/refractory follicular lymphoma, centered on data and experience with several novel agents.
Advertisement
Episodes in this series
Advertisement
Related to this article
CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Luciano Costa, MD, Discusses the Changing Treatment Paradigm in Myeloma
3
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
4
Dr Matous on Moving T-Cell Redirection Into Frontline Myeloma Care
5